Compound class:
Synthetic organic
Comment: MIDD0301 is a positive allosteric GABAAR modulator [1]. MIDD0301 targets specific GABA receptor subtypes (α4- and α5-containing receptors) that are selectively expressed in airway smooth muscle, airway epithelium, and inflammatory cells [2-3], and in this way offers the potential to alleviate asthma pathophysiology with a reduced likelihood of causing systemic side effects. It acts both as a bronchodilator and as an anti-inflammatory agent.
|
|
Immunopharmacology Comments |
Orally administered MIDD0301 reduces smooth muscle constriction and inflammation in a murine asthma model [1]. GABAA receptor modulators such as MIDD0301 offer an alternative approach to asthma management, that does not rely on compliant use of inhaled costicosteroids or LABAs, or suffer from the level of systemic adverse effects as caused by other anti-asthma therapeutics including the leukotriene receptor antagonists (montelukast, zafirlukast) or injectable biologic drugs (omalizumab, mepolizumab). |